Insmed Inc (INSM)vsNovaBridge Biosciences (NBP)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
NBP
NovaBridge Biosciences
$2.64
+4.76%
HEALTHCARE · Cap: $295.14M
Smart Verdict
WallStSmart Research — data-driven comparison
NBP leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
NBP
Avoid27
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : NBP
The strongest argument for NBP centers on Price/Book, Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : NBP
The primary concerns for NBP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while NBP is a value play — different risk/reward profiles.
NBP carries more volatility with a beta of 1.67 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
NBP generates stronger free cash flow (13M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
NovaBridge Biosciences
HEALTHCARE · BIOTECHNOLOGY · China
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is headquartered in Rockville, Maryland.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?